A383930 Stock Overview
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
DT&CRO CO., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,840.00 |
| 52 Week High | ₩24,400.00 |
| 52 Week Low | ₩3,415.00 |
| Beta | 0 |
| 1 Month Change | 17.01% |
| 3 Month Change | -11.91% |
| 1 Year Change | 36.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 13.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| A383930 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 32.2% | 0.5% | 0.8% |
| 1Y | 36.1% | -1.2% | 6.3% |
Return vs Industry: A383930 exceeded the KR Life Sciences industry which returned -1.2% over the past year.
Return vs Market: A383930 exceeded the KR Market which returned 6.3% over the past year.
Price Volatility
| A383930 volatility | |
|---|---|
| A383930 Average Weekly Movement | 14.7% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A383930's share price has been volatile over the past 3 months.
Volatility Over Time: A383930's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | n/a | www.dtncro.com/ko |
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. It conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd.
DT&CRO CO., Ltd. Fundamentals Summary
| A383930 fundamental statistics | |
|---|---|
| Market cap | ₩99.81b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A383930 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A383930 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A383930 perform over the long term?
See historical performance and comparison